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Thomas Fehr6, Reto M Venzin7 and Sabina De Geest1,8*Abstract
Background: Poor sleep quality (SQ) and daytime sleepiness (DS) are common in renal transplant (RTx) recipients;
however, related data are rare. This study describes the prevalence and frequency of self-reported sleep
disturbances in RTx recipients.
Methods: This cross-sectional study included 249 RTx recipients transplanted at three Swiss transplant centers. All
had reported poor SQ and / or DS in a previous study. With the Survey of Sleep (SOS) self-report questionnaire, we
screened for sleep and health habits, sleep history, main sleep problems and sleep-related disturbances. To
determine a basis for preliminary sleep diagnoses according to the International Classification of Sleep Disorders
(ICSD), 164 subjects were interviewed (48 in person, 116 via telephone and 85 refused). Descriptive statistics were
used to analyze the data and to determine the frequencies and prevalences of specific sleep disorders.
Results: The sample had a mean age of 59.1 ± 11.6 years (60.2% male); mean time since Tx was 11.1 ± 7.0 years.
The most frequent sleep problem was difficulty staying asleep (49.4%), followed by problems falling asleep (32.1%).
The most prevalent sleep disturbance was the need to urinate (62.9%), and 27% reported reduced daytime
functionality. Interview data showed that most suffered from the first ICSD category: insomnias.
Conclusion: Though often disregarded in RTx recipients, sleep is an essential factor of wellbeing. Our findings show
high prevalences and incidences of insomnias, with negative impacts on daytime functionality. This indicates a
need for further research on the clinical consequences of sleep disturbances and the benefits of insomnia
treatment in RTx recipients.
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Poor sleep quality is common among renal transplant
(RTx) recipients, with a prevalence ranging from 30%
to 62% [1-4] as measured using the Pittsburgh Sleep
Quality Index (PSQI). Subjective sleep quality (SQ) is
an evaluation of sleep by the affected individual [5],
covering elements such as total sleep time, sleep onset
latency, total waking time, sleep efficiency and disrup-
tive events. Daytime sleepiness (DS) involves difficulty
maintaining a desired level of wakefulness, i.e., the feel-
ing of drowsiness with a tendency to doze [6].* Correspondence: sabina.degeest@unibas.ch
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reproduction in any medium, provided the orOne cross-sectional study using the PSQI in a Swiss
transplant center reported a poor SQ prevalence of 47.4%
[7]. As measured using the Epworth Sleepiness Scale
(ESS), [8] data from three Swiss transplant centers showed
a prevalence of 52% for poor SQ [8] and 50.9% for daytime
sleepiness (DS). Most cross-sectional studies suggest that
poor SQ is higher pre-RTx (49%-78% [3,9,10]) than post-
RTx (30%-52% [1,11]). Similarly, insomnia (difficulty fall-
ing asleep, staying asleep, waking up before the desired
time and being left tired during the day) in RTx candidates
[12] has a prevalence of 15% in patients on maintenance
dialysis, compared to 8% post-RTx [13]. Post-RTx SQ re-
mains constant [14]. Supporting these findings, Sabbatini
et al. (2005) showed that sleep significantly improved from
pre- (PSQI mean: 8.52 ± 3.81, P < 0.001) to post-RTx
(PSQI mean: 6.46 ± 3.71, P < 0.001), although it remainedral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[3]. Finally, poor SQ has been linked to pre-RTx impaired
health status [14,15], with post-RTx health status impro-
ving alongside SQ [13,16].
The most frequent sleep disorders among hemodialysis
patients are conditioned insomnia (unconscious asso-
ciation of bedtime with negative feelings), obstructive
or central sleep apnea (repeated cessation of breathing
during sleep), restless leg syndrome (an irresistible
urge to move the legs) and periodic limb movement
disorder (involuntarily limb movements) [17]. In pa-
tients with end-stage renal disease, several uremic and
non-uremic factors are thought to contribute to the
pathogenesis of sleep disorders [17]. Sleep apnea ap-
pears to be related to displacement of fluids which
destabilize the control of breathing and narrow the
upper airway [18]. Restless leg syndrome and periodic
limb movement disorders are correlated with anemia,
iron deficiency, and peripheral and central nervous
system abnormalities. Therefore, most such disorders
improve post-RTx [18]. Excessive daytime sleepiness
occurs in approximately 50% of patients with end-
stage renal disease [19], the etiology of which appears
related to both uremia and sleep fragmentation [19].
Self-report screening questionnaires to assess sleep pro-
blems are an efficient preliminary step in a sleep diagnos-
tic process before the first assessment interview. However,
screening survey data analyses cannot do more than gene-
rally categorize sleep complaints. A detailed diagnosis of a
sleep disorder requires sleep experts and specific diagnos-
tic tools. In sleep medicine, diagnosis follows the Inter-
national Classification of Sleep Disorders (ICSD), which
groups disorders into eight categories: (1) Insomnias; (2)
Sleep Related Breathing Disorders; (3) Hypersomnias (ex-
cessive daytime sleepiness); (4) Circadian Rhythm Sleep
Disorders; (5) Parasomnias (strange movements, behav-
iors, emotions, perceptions, and dreams during sleep); (6)
Sleep Related Movement Disorders; (7) Isolated Symp-
toms, Apparent Normal Variants and Unresolved Issues;
and (8) Other Sleep Disorders [20]. ICSD diagnosis guide-
lines require a clinical assessment interview and may
specify diagnostic tools (e.g., polysomnography [21] or
biophysiological measurement [22]) to differentiate sleep
disorders from others with similar symptoms.
In summary, sleep quality normally improves after RTx;
[3] however, a high proportion of the current study’s RTx
recipients were still suffering from sleep disorders several
years post-Tx [8]. Prior to this study, no self-reported data
existed on sleep disturbances among (post-Tx) RTx recipi-
ents. Therefore, the aims of this study were:
1) to describe the frequency of self-reported sleep
disturbances in RTx recipients screened with the
Survey of Sleep (SOS); and2) based on structured sleep assessment interviews,
to measure the prevalence of sleep disorders in
RTx recipients.
Methods
Design, setting and sample
This study used a sequential cross-sectional multicenter
design with a sample of 249 adult home-dwelling RTx
patients, all of whom were participating in a larger study
on sleep and daytime sleepiness. The inclusion criteria
were: (1) RTx took place at one of the three participating
Swiss transplant centers, (2) a functioning renal graft at
least 6 months post-Tx, (3) the ability to understand and
read German, (4) 18 years of age or older, and (5) par-
ticipation in the preceding study with poor SQ (PSQI >5
[23]) and/or DS (ESS > 6 for increased DS [24]) scores.
Candidates were excluded if they were undergoing dialy-
sis or had not signed the written informed consent form.
The stage sampling approach used was based on can-
didates’ PSQI and ESS scores, both of which were
assessed as a part of the larger study [8]. The PSQI is a
self-rated questionnaire consisting of 19 items, assessing
a wide variety of factors related to sleep quality over a
1 month period, including estimates of sleep duration
and latency, and of the frequency and severity of specific
sleep-related problems. These 19 items are grouped into
seven component scores, each weighted equally on a 0–
3 scale. The seven component scores are then summed
to yield a global PSQI score, which has a range of 0–21;
higher scores indicate worse sleep quality. A cut-off of > 5
points is used to classify patients as having poor sleep
quality [23]. The ESS is a validated eight-item question-
naire to measure a subject’s expectation of dozing (falling
into a light sleep) in eight hypothetical situations. Dozing
probability ratings range from 0 (no probability) to 3 (high
probability). An ESS total score ≥ 6 indicates DS [25]. A
score ≥ 10 indicates that a person tends to become very
sleepy and should seek medical advice [25]. All 249
provided self-reported Survey of Sleep (SOS) data; a sub-
sample (n = 164) additionally participated in a sleep assess-
ment interview (83 declined participation).
Variables and measurements
Age (in years), gender, years since transplantation, body
mass index (kg/m2), creatinine (μmol/l), hemoglobin (g/l)
and drugs (including sleep drugs) were retrieved from the
participants’ hospital medical charts. Comorbidity data
were also extracted from patients’ charts and categorized
using the Charlson comorbidity index [26], which assigns
various weights to specific conditions. Each of the 19
noted conditions was assigned a score of 1, 2, 3, or 6, de-
pending on the associated mortality risk. For each patient
the scores were summed to provide his or her overall co-
morbidity score [26]. Sleep quality and daytime sleepiness
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three groups: 1) PSQI ≤ 5 (good SQ) & ESS ≥ 6 (DS); 2)
PSQI > 5 (poor SQ) & ESS < 6 (no DS); 3) PSQI > 5 (poor
SQ)& ESS ≥ 6 (DS).
Survey of sleep (SOS)
The self-reported Survey of Sleep (SOS) questionnaire
was developed at the University of Pittsburgh and trans-
lated into German by the second author. It is often used to
report sleep symptoms in insomnia patients, [22] and stu-
dies often employ it as a preparatory step before carrying
out sleep assessment interviews [27,28]. The questionnaire
consists of 7 sections: (1) sleep overview (existence of
problem(s) (yes/no), general sleep problem (main com-
plaint); duration (less/more than 1 year), course (getting
worse, same, better, irregular), and frequency of the sleep
problem (once/month, several times/week, nightly)); (2)
sleep habits (including bedtime, get-up time and sleep la-
tency in hours and minutes, whether the subject sleeps
better in another location (yes/no), regularity of bedtimes
(yes/no); (3) sleep disturbances (sleep-related symptoms
and a list of 45 potential disturbances); (4) daytime func-
tion (typical feelings on getting up (energetic, optimistic,
refreshed, low energy, irritable, depressed, confused, anx-
ious); nap behavior (intentional or unintentional naps,
dreaming during the naps (yes/no), feeling more alert after
the nap (yes/no), daytime function (sleepiness (not at all,
slightly, moderately, extremely), accidents because of
sleepiness (yes/no), fatigue (not at all, slightly, moderate,
extremely), having to close eyes during the day to relax
(yes/no), impaired daytime function (yes/no), most func-
tional period of the day (early or late morning, afternoon
or evening; night; no particular time), (5) health habits
(use of sleeping drugs (Yes/No), caffeine (amount in cups),
nicotine (number of cigarettes per day), alcohol use (glass
unit per day), (6) sleep history (select the main complaint);
and (7) medical history (diagnoses, drugs) [29].
The estimated time necessary to complete the SOS is
30 minutes. There is no sum scoring of the items and as
of the time of writing no validity or reliability measures
are available for it, as it was developed as a guide for an
sleep assessment interview and not as a diagnostic tool
[22]. The complete Survey of Sleep (SOS) questionnaire
is available on request from the second author.
Sleep assessment interview
Data from the SOS were used to prepare and structure the
sleep assessment interview. All responses indicating pos-
sible sleep disturbances were addressed and elaborated on
in the interview, which was structured to follow the 7 SOS
sections, and lasted approximately one hour. The informa-
tion generated by the interview helped to exclude some
sleep disorders; however, as no follow-up visits took place
and no further sleep diagnostic measurements or toolswere used, the given diagnoses according to the ICSD cri-
teria [20] should be regarded as preliminary.
The interviewer (first author) was trained to perform
sleep assessment interviews by a certified sleep specialist
and somnologist at the Hirslanden Sleep Disorders Center
in Zollikon, Switzerland. This training included an over-
view of sleep disorders and of the techniques used to diag-
nose them. The second author checked a random sample
of the completed interview transcripts and evaluated the
comprehensive justification (to provide inter-rater reliabi-
lity) of the preliminary sleep diagnoses. He also provided
back-up assistance in view of resolving difficulties in as-
sessment or categorization of sleep disorders.
Data collection
Patients were informed at the start of the research pro-
ject [8] that they might be invited for a further screening
and assessment if their initial data indicated poor SQ
and/or DS (see flowchart, Figure 1). Each such patient
received a package containing an information letter,
informed consent documents, a pre-stamped return en-
velope and the Survey of Sleep questionnaire (SOS).
Candidates were included in the study if they signed the
informed consent form, completed the SOS and re-
turned the documents.
Data collection started in June 2011 at the first trans-
plant center and ended in June 2012 at the third. Patients
who had not responded within 2 months of the document
mailings were contacted by phone to ask whether they had
received the material and would still be willing to complete
the questionnaire. Each eligible patient (N = 249) was
contacted to set up a sleep assessment meeting, which
could be conducted either in person or via telephone. Only
48 agreed to in-person interviews; 116 agreed to a phone
interview. After 10 unsuccessful call attempts, the patients
were categorized as unreachable or it was noted that they
had declined to participate (n = 85). According to each
participant’s wishes, the first author either met him/her at
a predetermined place or called at the predetermined time.
The study was approved by the ethics committees of all
three transplant centers (Ethikkommission beider Basel;
Kantonale Ethikkommision Bern; Kantonale Ethikkom-
mision Zürich). Data were anonymized following the inter-
view and stored in an electronic databank. Participants
given preliminary diagnoses were encouraged to consult
their nephrologists regarding their sleep problems. Any
patient who wished also received a list of certified sleep
disorder centers in Switzerland for further examination
and treatment.
Statistical analysis
Descriptive statistics (means, standard deviations (SD), me-
dians, quartiles, and frequencies) were used as appropriate,
based on measurement levels and variable distributions.
Figure 1 Flowchart of the sample.
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respondents were performed via t-test, Goodman and
Kruskal's gamma test, or Mann–Whitney U test. Missing
values were left blank and analysis was performed on the
values given. SPSS® Statistics software (Version 19.0.0,
IBM Corporation, Somers NY) was used for statistical
analysis, with all critical probability levels set to 5%.
Results
Of 688 RTx recipients invited to participate in this study,
249 (36.2%) agreed. Of 145 RTx with PSQI ≤ 5 (good
SQ) & ESS ≥ 6 (excessive DS), 18 (12.41%) participated;
of 218 with PSQI > 5 & ESS < 6, 78 (35.78%) participated;
and of 325 with PSQI > 5 & ESS ≥ 6, 153 (47.08%) par-
ticipated (Figure 1). Participants did not differ signifi-
cantly from non-participants regarding age, gender, years
since transplantation, comorbidities or daytime sleepi-
ness. However, poor SQ (PSQI score >5) was signifi-
cantly more prevalent among participants (Gamma: 479,df: 48; p = 0.0001). Of the 249 participants who filled in
the SOS questionnaire, 164 (65.8%) participated in the
subsequent sleep interview (Figure 1). The patients with
PSQI > 5 (poor SQ) & ESS ≥ 6 (excessive DS) scores also
had the highest participation rate in the assessment
interview (65.8%). Most in-person sleep assessment in-
terviews (n = 43) were performed with patients from
center 1 in connection with a nephrology follow-up visit,
where the first author has a clinical position. Participa-
tion in the sleep interview was much lower for patients
in centers 2 and 3, as each interview required 1–4 hours
of travel either for the patient or for the interviewer, and
no possibilities existed to connect the interviews with
nephrology follow-ups.
The participants had a mean age of 59.1 ± 11.6y; 60.2%
were male and the mean time since RTx was 11.1 ±
7.0 years (Table 1). Immunosuppressive therapy, sleep
drugs and co-medications, health habits and sleep his-
tory data are listed in Table 1. Sleep drug frequency, as
Table 1 Characteristics of the sample [chart review and SOS part 5 (health habits), 6 (past sleep history) & 7
(medical history)]
All (N = 249) Frequency Percentage
Male 151 60.2
Mean Std
Age in years 59.6 12.1
Years since RTx 11.1 7.0
Body Mass Index (kg/m2) 25.9 5.2
Creatinine (μmol/l) 125.0 81.6
Haemoglobin (g/l) 127.6 16.5
Median (25Q-75Q)
Charlson Comorbidities Index 1 0-2
Immunosuppressive drugs Frequency Percentage
Cyclosporin 103 41.4
Tacrolimus 93 37.3
Sirolimus, Everolimus 23 9.2
Mycophenolat 152 61.0
Azathioprine 38 15.3
Corticosteroids 78 31.3
Co-medication chart review
Statin 97 39.0
ACE inhibitor 61 24.5
Angiotensin receptor blocker 68 27.3
Calcium channel blocker 43 17.3
Beta blocker 92 36.9
Anticoagulants 58 23.3
Antidepressants 14 5.6
Diuretics 42 16.9
Sleep drugs 9 3.6
Self-reported sleep drug use 82 32.9
Caffeine use (>2 cups/d) 132 62.3
Nicotine use 31 12.4
Alcohol use (>1 glass/day) 64 25.8
Sleep history in childhood
Insomnia 24 9.6
Sleepwalking 16 6.4
Bed-wetting 24 9.6
Talking in your sleep 29 11.6
Nightmares 21 8.4
Night terrors (screaming in the middle of the night and being difficult to awaken) 6 2.4
Head-banging or body rocking 8 3.2
Seizures during sleep, while falling asleep, or while waking up 5 2.0
Daytime sleepiness 12 4.8
Snoring 12 4.8
Breathing difficulties 5 2.0
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epines and 2.0% for other sleep drugs. The prevalence of
self-reported sleep medication in the SOS was 32.9%.
Prevalence and percentage of sleep problems and sleep
habits [SOS part 1 & 2]
The most frequent sleep problem was difficulty staying
asleep (49.4%), followed by difficulty falling asleep (32.1%)
(Table 2). Most RTx recipients (61.4%) had experienced
their sleep problems longer than 2 years without change
(45%) and for 43.8% the problems occurred every night.
Prevalence and percentage of sleep symptoms [SOS part 3]
Of 45 sleep-related symptoms, the most prevalent were
the need to urinate (62.9%), leg cramps during sleep
(37.8%), frequent tossing and turning in bed (37.1%),
feeling too hot or too cold (33.2%) and awakening for no
particular reason (29.7%) (Table 3).
Prevalence and percentage of daytime function [SOS part 4]
At wake-up time in the morning, 68 participants (26.2%)
felt low energy, while an equal number felt optimistic.
Only 16.9% napped unintentionally during the day;
47.2% napped intentionally. Half (49.8%) of all nappers
felt more alert after a nap. During the day, 16.1% felt ex-
treme sleepy, 16.9% intensely fatigued and 27.8% im-
paired in their daytime functions (Table 4).
Prevalence and percentage of preliminary sleep
diagnoses according to the ICSD
The most prevalent preliminary sleep diagnosis was
chronic insomnia (42.5%), followed by circadian sleep-
wake disturbances. Table 5 presents the preliminary
sleep diagnoses based on a single assessment interview.
Discussion
To our knowledge, this is the first study to focus on sleep
problems in RTx recipients by using a detailed sleep ques-
tionnaire (SOS) and subsequent sleep assessment inter-
view. This study describes the frequency of self-reported
sleep disturbances in RTx recipients screened with the
Survey of Sleep questionnaire (SOS) and the frequency of
presumed sleep diagnoses based on the sleep interview.
As shown in Table 1, of the 688 patients invited to par-
ticipate, roughly 50% (n = 325) registered poor SQ and DS.
Figure 1 shows an increasing proportion of participants in
the “poor SQ (PSQI > 5) & and DS (ESS ≥ 6)” group. Of
these 325, 153 (47.1%) filled in the SOS and 108 (70.6%)
participated in the assessment interview. In addition, poor
SQ was significantly more prevalent in participants com-
pared to non-participants. This would support a hypoth-
esis that, even where no therapeutic benefit can be hoped
for, patients are more likely to participate in studies dir-
ectly relevant to their personal experience.Prevalence and percentages of sleep problems and sleep
habits [SOS part 1]
The most prevalent sleep problem was difficulty staying
asleep, followed by problems falling asleep. Both are char-
acteristic of insomnia [20]. Other characteristics of insom-
nia common in this group were the extended duration of
the sleep problem (61.4% reported durations greater than
2 years), the severity of the sleep problem (26.9% called
their problems severe), the high prevalence of nightly
sleeping pill use (32.9%), sleep latency of 28 ± 19.3 minutes,
a high number of awakenings (2.8 ± 1.8) per night, long
sleep latency after awakening (21.9 ± 16.4 minutes), and
high ratios of time in bed to hours of sleep (8.3 ± 1.3 hours)
to hours of sleep 6.4 ± 1.5. These results corroborate those
of Moul et al. (2002), [30] who reported that 68% of in-
somnia patients exhibited long-term sleep problems (more
than 1 year), severe sleep problems (81%), high nightly use
of sleeping pills (89%), long sleep latency (53.3 ± 51.8 mi-
nutes), high numbers of awakenings (2.7 ± 1.7) per night,
long sleep latency after awakening (56.0 ± 64.7 minutes),
and high ratios of time in bed to hours of sleep (8.2 ±
1.9 hours in bed: 5 ± 1.7 hours of sleep). The average sleep
duration of 6.4 ± 1.5 is very low, as studies have shown
that chronic restriction of sleep to 6 h or less per night
produces cognitive performance deficits equivalent to up
to 2 nights of total sleep deprivation [31]. Sleep deficits
seriously impair waking neurobehavioral functions (lapses
in behavioral alertness) in healthy adults [31].
Prevalence and percentages of sleep habits [SOS part 2]
One third of participants (n = 82) reported using sleeping
pills; however, the medical chart data showed that very few
(n = 9) had informed their nephrologists regarding their
sleep problems or use of sleep medication. During their
post-transplant hospitalization, all RTx recipients receive
education regarding over-the-counter medication and
medication prescriptions from other physicians, during
which they are advised always to consult their nephrologist
about possible interactions with their immunosuppressive
drugs [32]. This discrepancy may indicate that patients are
reluctant to bring up sleep problems, that they do not see
sleep disorders as a topic that nephrologists can deal with,
or that the nephrologists themselves simply consider sleep
disorders a normal side effect of RTx immunosuppressive
regimens. Compared to the general population, our preva-
lence of 32.9% self-reported sleep medication use is very
plausible: sleep medications are used regularly by 3.2% of
subjects 44 or younger, 13.3% of subjects between 45 and
64, 22% of those between 65 and 74 and 32% of indi-
viduals 75 or older [33].
Prevalence and percentage of sleep symptoms [SOS part 3]
The most prevalent night-time symptom was nocturia.
The frequency of its occurrence is key to further diagnosis.
Table 2 General description of the sleep problem [SOS part 1 (overview) & 2 (sleep habits)]
General sleep problem Frequency Percentage
Having an actual problem with sleep or wakefulness 179 69.1
Main sleep problem
Difficulty falling asleep 83 32.1
Difficulty staying asleep 128 49.4
Awakening early and being unable to fall back asleep 76 29.3
Excessive long sleep at night 21 8.1
Unusual behavior or experiences during sleep (e.g., nightmares, sleepwalking) 30 11.6
Excessive sleepiness during waking hours 66 25.5
Other problems 34 13.1
Judgment of the sleep problem
Intense severity of the sleep problem (or problems) 67 26.9
Intense amount of interference with ability to function at home, at work, and with other people 48 19.3
Fairly intense sleepiness before bedtime 127 51.0
Better sleep outside compared to the sleep at home 11 4.4
Having regular sleep times 192 74.1
Times related to sleep Mean Std
Bedtime during the week 22.6 0.9
Bedtime at weekends 23.2 1.3
Time of lights off during the week 22.9 1.1
Sleep latency 28.1 19.3
Frequencies of sleep interruptions 2.8 1.8
Sleep latency after interruptions 21.9 16.4
Wakeup time during the week 6.5 1.2
Sleep duration 6.4 1.5
Get up time during the week 6.9 1.1
Get up time at weekends 8.0 1.1
Frequency Percentage
How long having sleep problem
Between 6 months and 2 years 74 29.7
Between 2 and 5 years 60 24.1
>5 years 93 37.3
Course of the problem
Becoming worse 15 6.0
Same 112 45.0
Improving 17 6.8
Irregular 79 31.7
Recurring regularly 8 3.2
Frequency
Every day/night 109 43.8
Sometimes in a week 24 9.6
Sometimes in a month 31 12.4
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Table 3 The 32 most prevalent sleep disturbances out of 45 [SOS part 3 (sleep disturbances)]
Sleep Disturbance of N = 249 Frequency Percentage
Need to urinate 163 62.9
Leg cramps during sleep 98 37.8
Frequent tossing and turning 96 37.1
Feeling too hot or too cold 86 33.2
Awaken for no particular reason (spontaneous awakenings) 77 29.7
Feeling anxious or emotionally tense, or worrying about things at bedtime 72 27.8
Physical nervousness and agitation in the evening or at night 68 26.2
Restless, uncomfortable, or “crawling” sensation in your legs during the evening or at night 62 23.9
Awakened by dreams (not nightmares) 56 21.6
Snoring 54 20.8
Feeling physically tense at bedtime 42 16.2
Awakening because of noise or light 38 14.7
Jerking or twitching in feet, legs, or arms during sleep 34 13.1
Large body jerks as you are falling asleep 33 12.7
Awakened by noises 32 12.4
Awakened by recurring dreams 31 12.0
Other pain during sleep 31 12.0
Muscle aches during or after sleep 30 11.6
Grinding teeth 26 10.0
Nightmares 26 10.0
Heartburns or other burning in chest, stomach 24 9.3
Headaches beginning during sleep 24 9.3
Palpitations, heart racing, or irregular heart beat 23 8.9
Other sleep disturbances 22 8.5
Talking in your sleep 19 7.3
Hallucinations as you are falling asleep or waking up, i.e., seeing or hearing things which turn out not to actually be real 15 5.8
Frequent cough 15 5.8
Episodes of confusion during sleep or upon awakening 14 5.4
Awakening choking, smothering, or gasping for air 13 5.0
Periods of not breathing during sleep 13 5.0
Difficulty breathing (including wheezing) 11 4.3
Difficulty swallowing 11 4.2
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diminished nocturnal bladder capacity [34] require further
testing to exclude urinary tract infections and prostate
hyperplasia [35]. Also very prevalent were leg cramps and
frequent turning in bed, indicating muscle fatigue, nerve
dysfunction or electrolytic imbalances [36]. However, these
symptoms could also be indices of restless leg syn-
drome, periodic limb movements, myositis, or periph-
eral neuropathy [36]. Similarly, turning or rocking in
bed could indicate parasomnia (undesirable physical or
behavioral phenomena occurring during the sleep
period) [37]. For the diagnosis of parasomnias a careful
physical examination is crucial and often a polysomnogram,including an expanded electroencephalographic montage, is
necessary to distinguish between parasomnias (non-REM
or REM) and nocturnal seizures [37].
Leg cramps during sleep were the second most preva-
lent sleep symptom (37.8%), followed by frequent tossing
and turning in bed (37.1%). These two symptoms could
be related to restless leg syndrome and/or periodic limb
movements. The prevalence of restless leg syndrome in
RTx recipients overall is 4.5% [38]. For periodic limb
movements the overall prevalence is unknown, although
there is an improvement from pre- to post-Tx [39]. Noc-
turnal leg cramps are often associated with vascular dis-
ease, lumbar canal stenosis, cirrhosis and hemodialysis
Table 4 Description of daytime function [SOS part 4 (daytime function)]
Frequency Percentage
Typical feelings at awakening in the morning
Optimistic 68 26.2
Low energy 68 26.2
Energetic 44 17.0
Refreshed 28 10.8
Irritable 18 6.9
Other 17 6.6
Depressed 16 6.2
Anxious 14 5.4
Confused 4 1.5
Nap behavior
Intentional napping 118 47.4
Unintentional napping 42 16.9
Falling 1–2 times a day asleep or nap during the day 62 24.9
Often dreaming when falling asleep or nap during the day 10 3.9
Feeling more alert and awake after falling asleep or nap 124 49.8
Daytime function
Extreme amount of sleepiness during daytime 40 16.1
Had an accident because of sleepiness or falling asleep 11 4.4
Intense amount of fatigue during the day 42 16.9
Have to close eyes during the day to relax 78 31.3
Impaired daytime functioning because of nighttime sleep disturbances, daytime sleepiness or fatigue 72 27.8
Best function during the day
Early morning 102 39.4
Late morning 83 32.0
Early afternoon 38 14.7
Late afternoon 41 15.8
Early evening 34 13.1
Late evening 18 6.9
During the night 4 1.5
No specific time 35 13.5
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The sensorimotor symptoms of restless leg syndrome
and/or periodic limb movements can be treated with
dopamine agonists, gabapentin and its derivatives, and
opioids [40]. To summarize, in-depth assessment of all
these listed symptoms is crucial for the right treatment
choice.
Prevalence and percentage of daytime function [SOS part 4]
Table 4 shows the high prevalence of daytime sleepi-
ness, tiredness and impaired daytime functioning,
highlighting the importance for affected patients to use
reminders (e.g., pillbox alarms, SMS reminder func-
tions, or other cues) to ensure punctual intake of theirimmunosuppressive drugs. An earlier study showed cor-
relations between DS and impaired immunosuppressive
medication adherence [Burkhalter H, Wirz-Justice A,
Cajochen C, Weaver T, Steiger J, Fehr T, Venzin R, De
Geest S: Daytime sleepiness is associated with immuno-
suppressive non-adherence in renal transplant recipi-
ents: a cross-sectional multi-center study. Submitted].
However, it is possible that compensating behaviors
such as increased use of mild stimulants (e.g., caffeine,
nicotine) (Table 1) account for the lower prevalence of
non-adherence (16%) than of DS (52%) [41].
Napping behavior and sleep duration depends on cul-
tural, environmental, occupational and health factors [42].
In this study, 47.4% of participants reported intentional
Table 5 Frequency of preliminary sleep diagnosis based on the interview grouped into the international classification
of sleep disorders categories
N = 164 Frequency Percentage
Insomnias
Psychophysiological insomnia or paradoxical insomnia 53 32.3
Adjustment insomnia 3 1.8
Inadequate sleep hygiene 5 3.0
Insomnia due to medical condition 9 5.5
Sleep Related Breathing Disorders
Obstructive Sleep Apnea, Adult 8 4.9
Other Sleep Related Breathing Disorders 5 3.0
Hypersomnias of Central Origin Not Due to a Circadian Rhythm Sleep Disorder, Sleep Related Breathing Disorder or
Other Cause of Disturbed Nocturnal Sleep
Behaviorally induced insufficient sleep syndrome 11 6.7
Idiopathic hypersomnia with long sleep time 7 4.3
Hypersomnia due to drug or substance use 1 0.6
Circadian Rhythm Sleep Disorders (CRSD)
CRSD delayed sleep phase type 22 13.4
CRSD advanced sleep phase type 3 1.8
CRSD irregular Sleep-Wake Type 8 4.9
Parasomnias
Nightmare Disorder 4 2.4
Parasomnia due to drug or substances 4 2.4
Confusional Arousals 4 2.4
Parasomnia due to med conditions 2 1.2
Sleep Related Movement Disorders 1 0.6
Isolated Symptoms, Apparent Normal Variants, and Unresolved Issues 0 0.0
Other Sleep Disorders 0 0.0
No presumed diagnosis 14 8.5
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tality [42]. However, a nap lasting several hours [43] might
interfere with nighttime sleep–a point which would have
to be borne in mind while counseling patients regarding
sleep hygiene. The ideal nap duration for adults is about
10–20 minutes and the timing depends on the quality of
sleep duration the preceding night, amount of prior wake-
fulness and morningness-eveningness tendencies [44].
Prevalence and percentages of preliminary sleep diagnoses
This study’s most prevalent sleep diagnosis was chronic
insomnia, followed by circadian rhythm sleep disorders.
The prevalence of insomnia in the general population is
15-20% [45] and prevalence of circadian rhythm sleep
disorders ranges from 3.1% in adults aged 40–64 to 16%
in adolescents [46]. Our prevalence of 42.6% insomnia
and 20.1% CRSD is only partially comparable based on
our group’s pre-selection criteria (RTx recipients having
poor SQ and/or DS). Various publications suggest RTx
recipients’ sleep disorders are related to medications(e.g., β-blockers [47], nonsteroidal anti-inflammatory
drugs [48], corticosteroids [49] and mycophenolic acid
[50]) and other clinical conditions [51,52]. Molnar et al.
[53] list numerous potential causes of sleep disorders in
this group, including pre-existing sleep disorders, trans-
plant surgery, hospitalization, anxiety and uncertainty,
fear of organ rejection, immunosuppressive medication,
deteriorating kidney function and co-morbid medical con-
ditions, psychosocial problems, psychiatric and neuro-
logical disturbances, lifestyle, diet, environmental factors
and aging. With so many possible contributing factors, the
most appropriate course of action might be a referral to a
sleep expert, who could counsel the patient on the full
range of behavioral and medical interventions available,
and help them to choose those best suited to their needs
[54]. Sleep interventions for RTx recipients are the same
as for the general population, apart from the risk of inter-
action with immunosuppressive therapy and the need to
consider the long-term side effects of their therapy (e.g.,
osteoporosis, new onset of diabetes, pain).
Burkhalter et al. BMC Nephrology 2013, 14:220 Page 11 of 12
http://www.biomedcentral.com/1471-2369/14/220Limitation of this study
Since only 249 RTx recipients filled in the question-
naire, of which only 164 (65.9%) gave interviews, the
generalizability of this study’s findings are limited. In
addition, the high prevalence of RTx recipients in the
“poor SQ (PSQI > 5) & and excessive DS (ESS ≥ 6)”
group showing an increasing proportion along the
study steps, limits the significance and comparability of
the presumed sleep diagnoses.
Suggested further research
Further research will be necessary to develop safe inter-
ventions for RTx recipients with sleep-wake distur-
bances, taking into account their impaired renal
function (limited organ survival), high risk of skin cancer
(a side-effect of immunosuppressive treatment) and need
to adhere to their medication regimens (high risk of
acute graft rejection). These interventions should in-
clude education [55] regarding sleep disorders and their
negative health impacts. Apart from established cogni-
tive and behavioral interventions for insomnia, new
chronotherapeutics treatments, particularly bright light
therapy and melatonin supplementation [56] should be
investigated. For RTx recipients, who already have a
high number of medications to ingest daily, light therapy
might be a realistic intervention to stabilize sleep-wake
rhythms compared to melatonin supplementation (one
more drug to ingest).
Conclusion
Our findings show high prevalence of insomnia and of
impaired daytime functionality. This indicates a need for
further research on the clinical consequences of sleep-
wake disturbances and the benefits of insomnia treat-
ment in RTx recipients.
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